Q-omics provides the consensus-scored RBM18 profile across patient tissues and cancer cell-line models. RBM18 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RBM18 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, RBM18 protein abundance shows 34,167 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, HNSC, and LUAD as cancer lineages where RBM18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM18 survival associations across molecular data types. RBM18 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM18 RNA expression–survival associations across cancer types. High RBM18 expression shows unfavorable associations in HNSC, ACC, STAD, KIRP and LGG, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RBM18 RNA expression.
This table summarizes RBM18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RBM18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM18 shows lower tumor expression in THCA, KIRC and KICH and higher tumor expression in HNSC, LIHC and CHOL. The HNSC box plot shows higher RBM18 RNA expression in tumor versus normal tissue (log2 FC = +0.709, t-test p < 0.001).
This table shows molecular features associated with RBM18 in patient tissues and cancer cell lines. In patient samples, RBM18 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, RBM18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_NSCLC_LUAD.
